A Randomised, Double-Blind, Placebo-Controlled, Single Dose Trial Evaluating Different Doses of Intravenously Administered VMX-C001 and to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of VMX-C001 in Healthy Subjects (Part 1) and in Combination With a Selected FXa Direct Oral Anticoagulant (DOAC) in Healthy Older Subjects (Part 2)
Latest Information Update: 22 Nov 2024
At a glance
- Drugs Recombinant coagulation factor X VarmX (Primary) ; Apixaban; Edoxaban; Rivaroxaban
- Indications Haemorrhage
- Focus Adverse reactions; Pharmacokinetics
- Sponsors VarmX
Most Recent Events
- 23 Jul 2024 Planned End Date changed from 1 Sep 2024 to 1 Aug 2026.
- 23 Jul 2024 Planned primary completion date changed from 1 Sep 2024 to 1 Aug 2024.
- 23 Jul 2024 Status changed from recruiting to active, no longer recruiting.